<DOC>
	<DOCNO>NCT00280410</DOCNO>
	<brief_summary>This multicenter , randomize , open-label study investigate superiority contrast enhancement effect E7337 tumor-like lesion Dynamic CT liver .</brief_summary>
	<brief_title>Study Investigating Effect E7337 Tumor Like Lesions Computed Tomography ( CT ) Liver</brief_title>
	<detailed_description />
	<criteria>1 . Patients tumorous lesion liver observe diagnostic imaging ultrasonography , etc. , conduct 1 35 day administration investigational agent , schedule undergo dynamic CT examination . 2 . Patients 20 80 year old time inform consent obtain . 3 . Patients weigh &gt; = 55.6 &lt; 105.0 kg time consent obtain investigational agent administer . Issues affect safety evaluation investigational agent : 1 . Patients undergone schedule undergo examination use another contrast agent 7 day administration investigational agent time followup examination perform day 8 administration . 2 . Patients strong possibility followup period , extend examination perform day 8 administration , would possible , ( i.e. , possible evaluate delay adverse drug reaction ) . 3 . Patients undergone schedule undergo surgical treatment therapy percutaneous ethanol injection therapy , percutaneous microwave coagulation therapy , radiofrequency ablation , transcatheter arterial embolization , etc. , time diagnostic image abdominal ultrasonography perform followup examination conduct day 8 administration . 4 . Patients unable discontinue take analgesic period morning investigational agent administer CT examination complete . 5 . Patients stop take biguanide antidiabetic drug , metformin hydrochloride buformin hydrochloride , three day study agent administration ( include administration day ) . 6 . Patients currently participate another clinical study . 7 . Patients participate another clinical study within 6 month prior provide inform consent participate study . General concern relate safety subject : 1 . Patients acute stage illness unstable symptom , patient lifethreatening condition ( expect emergency treatment may require time registration conclusion followup period , patient expect survive 3 month follow administration investigational agent , etc . ) 2 . Patients history hypersensitivity iodine iodinate contrast agent . 3 . Patients serious thyroid disease ( goiter , hyperthyroidism , etc . ) 4 . Patients serious cardiopathy ( New York Heart Association [ NYHA ] functional class IV heart failure , shock , cyanosis , peripheral circulatory insufficiency , ventricular tachycardia , ventricular fibrillation , complete atrioventricular block ) 5 . Patients serious hepatopathy [ symptom liver failure ( fulminant hepatitis ) disturbance consciousness correspond grade 3 Criteria Grading Adverse Drug Reactions Medicinal Products . ] 6 . Patients moderate serious nephropathy ( acute kidney failure , chronic kidney failure , hydronephrosis , nephrotic syndrome , uremia serum creatinine level 2.0 mg/dL , correspond grade 2 Criteria Grading Adverse Drug Reactions Medicinal Products . ) 7 . Patients bronchial asthma 8 . Patients acute pancreatitis 9 . Patients macroglobulinemia 10 . Patients multiple myeloma 11 . Patients tetany 12 . Patients pheochromocytoma suspect pheochromocytoma 13 . Pregnant potentially pregnant woman , nurse mother 14 . Patients history medicine hypersensitivity 15 . Patients serious myasthenia gravis 16 . Patients judge investigator reason ineligible participation subject study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>